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Abstract 
Cystic Fibrosis is a multi organ hereditary disease caused by a mutation in the 
gene coding for Cystic Fibrosis Transmembrane conductance Regulator protein 
(CFTR).The different mutations of the CFTR gene were divided into 6 classes on 
the basis of molecular defects and the consequent functional alterations. 
Depending on the type of mutation, the protein may be more or less expressed and 
functioning. This involves varying degrees of disease severity and not only 
between different mutations but also between patients having the same mutation. 
Research carried out to date to try to cure the basic defect has led to good but not 
sufficient results. In order to test promising drugs able to rescue the expression 
and function of CFTR are necessary easy and fast methods and the use of primary 
cells from the individual patients. Leukocytes are recognized in the scientific 
literature as key component of the pathogenetic events associated to cystic 
fibrosis. Leukocytes, especially monocytes, represent an easily accessible source 
of primary cells that might be exploited to monitor CFTR expression and activity. 
Based on previous work I was involved in the development of a new assay to 
measure CFTR activity suitable to be used in primary cells. The readout of this 
method is based on residue quantity of iodide present in the supernatant, after 
proper stimulation, quantified by the quenching of the fluorescence of Halide 
Sensitivity Yellow Fluorescence Protein (GST-HS-YFP). The specificity of the 
assay for CFTR activity was tested using two different CFTR inhibitors, CFTR-
172 and PPQ-102, in MM6 cells and after silencing of MM6 with CFTR siRNA. 
These data were confirmed also in primary Leukocytes, where we recorded a 
significant difference between WT and CF PBMCs and Monocytes (p<0,005). 
GST-HS-YFP assay can represent easy and fast methods to measure the CFTR 
function in Leukocytes from CF patients during clinical trials and another useful 
technique applicable in different cell types to perform new drugs screening. 
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Riassunto 
La fibrosi cistica è una malattia ereditaria multiorgano causata da una mutazione 
nel gene codificante per la proteina di regolatore di conduttanza transmembrana 
della fibrosi cistica (CFTR). Le diverse mutazioni del gene CFTR sono state 
divise in 6 classi sulla base di difetti molecolari e delle conseguenti alterazioni 
funzionali. A seconda del tipo di mutazione, la proteina può essere più o meno 
espressa e funzionante. Questo comporta diversi gradi di gravità della malattia e 
non solo tra diverse mutazioni ma anche tra pazienti che hanno la stessa 
mutazione. La ricerca effettuata fino ad oggi per cercare di curare il difetto di base 
ha portato a risultati buoni ma non sufficienti. Al fine di testare farmaci 
promettenti in grado di aumentare l'espressione e la funzione di CFTR sono 
necessari metodi facili e veloci e l'uso di cellule primarie derivanti dai singoli 
pazienti. I leucociti sono riconosciuti nella letteratura scientifica come 
componente chiave degli eventi patogenetici associati alla fibrosi cistica. I 
leucociti, in particolare i monociti, rappresentano una fonte facilmente accessibile 
di cellule primarie che potrebbero essere sfruttate per monitorare l'espressione e 
l'attività di CFTR. Sulla base di lavori precedenti sono stata coinvolta nello 
sviluppo di un nuovo test per misurare l'attività di CFTR. Il risultato di questo 
metodo si basa sulla quantità residua di ioduro presente nel surnatante, dopo 
opportuna stimolazione, quantificata dalla estinzione della fluorescenza della 
proteina a fluorescenza gialla ad alta sensibilità (GST-HS-YFP). La specificità del 
dosaggio per l'attività CFTR è stata testata utilizzando due diversi inibitori CFTR, 
CFTR-172 e PPQ-102, in cellule MM6 e dopo il silenziamento di MM6 con 
siRNA CFTR. Questi dati sono stati confermati anche nei leucociti primari, dove 
è stata registrata una differenza significativa tra WT e CF PBMC e Monociti (p 
<0,005). Il dosaggio GST-HS-YFP può rappresentare un metodo semplice e 
veloce per misurare la funzione CFTR nei leucociti da pazienti CF durante gli 
studi clinici e un'altra tecnica applicabile in diversi tipi di cellule per eseguire lo 
screening di nuovi farmaci. 
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Introduction 
Cystic Fibrosis (CF) is one of the most common multi-organ hereditary diseases 
in the Caucasian population, with an incidence equal to one case per 2500-2700 
births (Ratjen and Döring 2003). This pathology is caused by a mutation in the 
gene coding for Cystic Fibrosis Transmembrane Regulator protein (CFTR), a 
chloride channel that is expressed in different cell types. Cystic fibrosis leads to 
pathological changes in organs that express CFTR, including secretory cells, 
sinuses, lungs, pancreas, liver, and reproductive tract. The absence of functional 
CFTR in airway epithelia leads to abnormal airway surface liquid, which favors 
chronic infection with Pseudomonas aeruginosa (PA), Staphylococcus aureus, 
Burkholderia cepacia and other bacteria. This chronic infection in CF lungs is 
associated with an exaggerated inflammatory response leading to pulmonary 
disease; the first cause of death in CF. The pancreas is affected in 85% of cases 
with a stagnation of pancreatic juices in the ducts. The lack of pancreatic juices in 
the intestinal canal leads to a malabsorption of fats, and to the consequences of 
fat-soluble vitamins, proteins and, to a lesser extent, sugars. Over time, the 
pancreas, more and more affected, secretes in smaller quantities, is a form of 
diabetes usually insulin-dependent. The disease affects the reproductive tract:98% 
of male subjects are sterile for azoospermia (Dodge 1995); women can have 
children but fertility is still reduced (Kopito, Kosasky, and Shwachman 1973). 
Structure and function of CFTR 
Between the end of the '70s and the beginning of the' 80s numerous investigations 
were carried out to try and identify the gene responsible for CF (Mayo et al. 
1980). The analysis of polymorphisms carried out using restriction enzymes 
(RFLP) has mapped the locus CF on chromosome 7q31 (Knowlton et al. 1985; 
Tsui, Buetow, and Buchwald 1986; Klinger et al. 1986) (NCBI reference 
sequence NC_000007.13 , accession number NM_000492.3). The gene is 188703 
base pairs long (Figure 1) and encodes a 1480 amino acid protein (NP_000483.3) 
known as the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) 
(Riordan et al. 1989). CFTR belongs to the MRP subfamily involved in drug 
resistance mechanisms and together with six other subfamilies (ABC1, MDR / 
 TAP, ALD, OABP, GCN20, White) constitutes the superfamily of genes that 
encode proteins commonly referred to as ATP
transporters. This superfamily includes proteins that are important from a clinical 
point of view, such as glycoprotein P (P
to many drugs (MDR) and tapasi
1986; Higgins et al. 1988)
 
Figure 1. Diagram showing CFTR gene and resulting protein (CFTR, cystic 
fibrosis transmembrane conductance regulator; MSD, membrane
domain; NBD, nucleotide binding domain; R domain, regulatory 
domain)(Maurya, Awasthi, and Dixit 2012)
CFTR is a glycosylated protein with relative mass (Mr) of about 170 kDa in 
which several regions shown in
composed of two r
transmembrane domains (Figure 2). Each of the two MSD regions is connected to 
a nucleotide binding domain (NBD1 and NBD2) that binds ATP. The regulatory 
-binding cassette (ABC) 
-gp), the protein responsible for resistance 
n (TAP) transporters (Gros, Croop, and Housman 
. 
. 
 Figure 2 have been identified. 
egions, MSD1 and MSD2, each of which includes 6 
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domain (R-domain) is rich in polar amino acids and interposing between NBD1 
and NBD2 connects the two MSD regions of CFTR. It is the presence of this R-
domain that places the CFTR protein in the ABC transporters superfamily. In fact, 
the CFTR protein has channel functions that transports chloride ions through the 
plasma membrane, but can also transport other anions, for example iodide and 
bicarbonate. 
 
Figure 2.The CFTR channel. Two-dimensional representation of the CFTR 
protein (NP_000483.3) in the plasma membrane (courtesy of Oxford University 
Gene Medicine, UK). 
Many of the mutations identified in CF patients are positioned in NBD1, while 
few have been identified in NBD2. This characteristic location of mutations is 
common in the ABC superfamily and indicates a separate role for the two binding 
domains. The most commonly found mutation is the deletion of 3 base pairs that 
code for the phenylalanine residue at position 508 of the amino acid sequence 
(F508del) in the exon that code for NBD1. The absence of this amino acid 
prevents the protein being formed from assuming a correct conformation 
("folding"). The defective CFTR protein does not continue its maturation path 
from the endothelial reticulum to the Golgi where it is normally glycosylated, but 
is instead ubiquitinated and directed towards its degradation in the proteasome. 
Therefore most of the defective protein is degraded and only a small part is 
expressed on the plasma membrane where it exerts its channel function. 
Facilitating the folding of the nascent protein through the use of pharmacological 
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correctors, F508del / F508del CFTR is able to reach the plasma membrane and 
function as a chloride channel, albeit less efficiently than the non-mutated CFTR 
protein. The NBDs contain a series of highly conserved motifs able to bind and 
subsequently hydrolyze ATP. Site-specific mutagenesis studies in these regions 
have indicated that ATP must bind to both NBDs to cause channel opening 
(Jordan et al. 2008). Exon 13 encodes the R domain that is located between NBD1 
and NBD2 (Figure 2). It contains several cAMP-dependent phosphorylation sites 
catalyzed by protein kinase A or C (PKA or PKC). The regulation of the activity 
of the CFTR ion channel in part depends on the degree of phosphorylation of the 
R domain and partly on the binding of ATP to the NDBs domains. The N-terminal 
portion of the R (RD1) domain is highly conserved among the species. About 
20% of the CFTR protein is composed of transmembrane domains (M1 - M12). In 
these domains the typical secondary α-helix structure prevails. Many of the 
residues within these domains form the channel lining and play an important role 
in regulating pore function. Six of these positively charged residues are well 
conserved between species. Mutations in two of the six residues were found in CF 
patients, for example R334Q / W and R347C / H / L / P. 
CFTR Mutation 
So far, 1964 different mutations in the CFTR gene have been identified: 786 
missense (40%), 311 frameshift (16%), 228 splicing (11%), 162 nonsense (8%), 
39 in / del (2%) frames, 50 large in / del (3%), promoter (1%), 269 sequence 
variations (14%), 104 unknown (5%). A first attempt to group the mutations of 
the CFTR gene on the basis of the molecular defects and consequent functional 
alterations produced the 6 classes listed in Table I. CF patients with mutations 
included in one or more of these classes would be differently sensitive to 
treatment with chemical compounds able to correct the molecular defect. Class I 
include nonsense mutations with premature stop codons that lead a mRNA 
degradation and consequent no protein expression (Bobadilla et al. 2002). Class II 
included a most common mutation F508del that affect CFTR protein processing 
due to misfolding which is recognized by endoplasmatic reticulum (ER) quality 
control retention and which targets protein with abnormal conformation to 
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degradation (Amaral 2004). Class III mutations disrupt channel regulation through 
impaired gating (G551D) (Bell, De Boeck, and Amaral 2015). Class IV mutations 
decrease Cl- ion conductance, Class V mutations reduce normal protein levels, 
often by affecting splicing and generating both aberrant and normal transcripts, 
whose levels vary amongst patients (Ramalho et al. 2002). Class VI mutations 
leads to decreased retention/anchoring at the cell surface, often associated with 
decreased protein stability at the plasma membrane or in a deletion mutant that 
takes out the CFTR protein initiation codon, so that the resultant protein lacks the 
N-tail required for cytoskeleton anchoring (Ramalho et al. 2009). 
Tab I 
Class Molecular defect Conseguence Exemple 
I 
Premature termination 
stop codon (PTC). 
Reduced or absent synthesis 
of CFTR 
W1282X, 
R553X, G542X 
II Mysfolding protein 
Abnormal CFTR 
conformation; reduced 
expression 
F508del, 
N1303K 
III 
Imparied regulation of 
CFTR 
Reduced or absent function 
G551D, 
G551S, 
G1349D 
IV 
decreased 
retention/anchoring at 
the cell surface 
Reduced channel 
conductance 
R117H, 
R334W, 
R347P 
V 
Alternative spicing of 
mRNA 
Reduced synthesis and 
expression of CFTR 
2789+5G→A, 
A455E 
VI 
high turnover of CFTR 
on plasma membrane 
Decreased protein stability 
120del23, 
N287Y... 
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Screening and diagnosis of CF disease  
Prenatal diagnosis. It is recommended for couples of healthy carriers who want a 
child, having a high risk of generating an affected individual (25% risk at each 
pregnancy). It is performed through the removal of corial villus (villocentesis) at 
the tenth week of pregnancy. The genetic test for cystic fibrosis is applied to the 
villus taken (analysis of the mutations of the CFTR gene carried by the parents). 
Neonatal screening. It has been introduced in most Italian regions. A drop of 
blood is taken from all infants on whom the immunoreactivetrypsin test - IRT is 
performed. If IRT has a value beyond the reference threshold in the healthy 
population, the suspicion of disease arises and the genetic test is performed on the 
same drop of blood. This is diagnostic of CF if two mutations are identified in the 
CFTR gene, one on each allele. The definitive confirmation of the diagnosis is in 
any case entrusted to the sweat test, carried out already at 20-30 days of life in the 
newborn (Geokas et al. 1979; King et al. 1979; Crossley, Elliott, and Smith 1979; 
Simpson et al. 2005). Birth screening allows early diagnosis of CF disease and at 
the same time initiates the program of controls and therapies, which have 
significantly improved the quality of life in patients, as soon as possible. 
Measurement of salt concentration, NaCl, in secretions of sweat glands. A 
concentration above the threshold equal to 60 mEq of Cl (-) per liter after 6 
months and at 50 mEqCl (-) / L in the first 6 months of life strongly orientates 
towards the diagnosis of cystic fibrosis. Chloride values below 40 mEqCl (-) / L 
(30 in the first months of life) exclude the disease, albeit with some rare 
exceptions. Intermediate values (also called "borderline") are not conclusive, 
because they may be affected by interferences, for example pharmacological, both 
in healthy and sick subjects. In these individuals it is therefore necessary to carry 
out genetic analysis which, if performed correctly, turns out to be a diagnosis of 
CF disease. In the last few years a new sweat test, named “bubble test” (Wine et 
al. 2013), is under investigation that might provide some advantages with respect 
to the standard Gibson and Cook method (Bergamini et al. 2017). 
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Nasal potential difference (NPD).In addition to measuring the concentration of 
NaCl in the sweat, a second diagnostic test can be performed: the measurement of 
the potential difference in the cells of the nasal mucosa (NPD) that is particularly 
useful in cases where the sweat test has given uncertain results (Naehrlich et al. 
2014). The mucosa of a CF patient's airway secretes less chloride and absorbs 
more sodium than normal; this imbalance involves measuring a more negative 
value of the tension through the nasal epithelium measured in the CF patient than 
that measured in a healthy individual. This test, certainly not very comfortable, 
also requires an important collaboration from the patient. Thus the patient's 
"compliance" can greatly influence the reproducibility of the results obtained with 
the measurement of NPD. Furthermore, its reference values have not yet been 
standardized globally and therefore each center has its own reference range of 
NPD values. 
Genetic analysis. Methods to identify mutations in the CFTR gene are based on 
the sequencing of gene fragments, have high specificity, and a discrete sensitivity 
of 70-80% of cases. The analysis of the whole gene, instead, requires long time, 
has high costs, needs equipped laboratories and experienced personnel in the 
interpretation of the results and therefore it is carried out only in selected cases 
and in highly specialized centers. 
Symptomatic therapy 
The patient with CF is advised to follow a high-calorie, high-fat diet associated 
with pancreatic enzymes at every meal, replacing those that the pancreas does not 
produce, and supplemented with fat-soluble vitamins (vit A, D, E, K ), mineral 
salts, especially in the young child, in hot weather and during sustained exercise. 
In addition, a strict therapeutic plan is applied which includes the following 
treatments: 
Physiotherapy and respiratory rehabilitation to remove mucus from the respiratory 
system. 
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Education to a lifestyle with an aptitude for movement and also for sport: physical 
exercise promotes a harmonious development of the sick person, facilitates the 
removal of secretions and the effectiveness of respiratory function. 
Aerosol therapy is applied to CF patients to thin the mucus, to dilate the bronchi 
or to administer antibiotics during acute and / or chronic lung infections. One of 
the drugs used for aerosol is human recombinant DNAs (Pulmozyme, Roche 
SpA). It acts by fragmenting the extracellular DNA resulting from the lysis of 
bacteria and granulocytes, decreasing the viscosity of the secretions and making 
antibiotic therapy more effective (Jones et al. 2005). This therapy is able to induce 
only a modest recovery of lung function by decreasing in some individuals the 
frequency of severe and recurrent acute respiratory attacks. 
Antibiotic therapy. Administered orally or systemically, in cycles or for prolonged 
periods, serves to reduce the charge and to contain bacterial aggressiveness.  
Anti-inflammatory therapy. It begins early in the course of the disease, before 
extensive irreversible lung damage occurs. Anti-inflammatory drugs that appear to 
slow the progression of the disease include oral corticosteroids, ibuprofen, and 
azithromycin, which, in addition to its antimicrobial effects, also possess anti-
inflammatory properties (Pressler 2011).  
In adolescents and adults, pancreas involvement can also cause diabetes, which 
requires daily insulin injections. The various complications require specific 
treatments: fluidization of intestinal contents in obstructive syndromes, 
fluidization of bile in hepato pathology, treatments against osteoporosis. 
In the case of very advanced lung disease with irreversible respiratory failure, 
lung transplantation is the last chance to lengthen life expectancy. 
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Therapies of the basic defect  
Gene therapy. It involves inserting the CFTR gene without CF (wild type) 
mutations into cells of a CF patient who have a defective CFTR gene. In theory 
this result can be obtained through two methods. In the former, recombinant viral 
vectors, for example adenovirus, are used, which by penetrating into the host cell 
introduce the coding sequence of the wild type CFTR; in the second, the insertion 
of the wild type CFTR gene occurs through the use of a cationic lipid, such as 
GL67A, which carries DNA nanoparticles (DNA complexed with peptides) and 
self-assembling complexes of polyethylenimine (Derichs 2013; Rogan, Stoltz, and 
Hornick 2011; Davies and Alton 2010; Rosenecker, Huth, and Rudolph 2006). So 
far no satisfactory results have been obtained with these two approaches, the 
overall duration of expression of the correct gene is relatively short and numerous 
side effects have been observed both using the viral vector and adopting strategies 
not based on adenoviruses (Griesenbach, Pytel, and Alton 2015)..Since the in-
depth study of the synthesis mechanisms of the CFTR protein and its chloride 
channel function, it was possible to identify new pharmacological targets useful to 
restore the correct synthesis and / or function of the mutated protein. 
Through high-throughput screening assays, a technique to rapidly identify active 
compounds, antibodies, or genes involved in a particular biomolecular process, 
and other "drug discovery" techniques, small molecules have been identified 
which, by acting on the basic defect, are potentially able to re-establish CFTR 
expression on the plasma membrane and/or its channel activity. These substances 
have been divided into two categories: agents that target the genetic mutation and 
compounds that act on the consequences induced by specific mutations in the 
CFTR protein (Sloane and Rowe 2010). 
In the last decade the researchers' attention has focused on the study of molecules 
called CFTR modulators. Starting from the study of the alteration mechanisms 
caused by the presence of particular classes of mutation of the CFTR gene, it was 
possible to identify active molecules on particular defects. It was observed that CF 
 individuals with particular mutations could benefit from treatment with molecules 
able to interfere with specific mechanisms of alteration of CFTR
Compounds capable of modulating the ex
of the CFTR channel are classified into three main
correctors and suppressors of early arrest codons (PTC readthrough) 
2013) . 
 
PTC suppressors. The Class I mutations or nonsense, are present in about 5
of the CF population, although the incidence is about 60% of the Israeli 
population (Michael 
As described above, mutations of class I are associated with the presence of a 
premature stop codon (PTC), whi
protein early. The truncated protein is malfun
plasma membrane of the cell. In the pas
possessed the ability to reverse the effect of the presence of P
random amino acid that allow the ribosome to continue to read the mRNA and 
synthesize the entire protein. In vitro studies subsequently showed that the 
expression of CFTR on the cell membrane
increased up to 35% 
Furthermore, gentamicin was able to induce the expression of the CFTR protein in 
a homozygous mouse mode
pression of CFTR and / or the function 
 groups (Figure 3): enhancers, 
Wilschanski and Kerem 2011; M. Wilschanski et al. 2011)
ch terminates the translation of the CFTR 
ctioned and does not reach the 
t it was observed that gentamici
TC by inserting a 
, when exposed to gentamicin
(Howard, Frizzell, and Bedwell 1996; Bedwell et al. 1997)
l for the G542X mutation (M. Wilschanski et al. 
16 
 (Pettit 2012). 
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-10% 
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2011). Subsequent studies have confirmed these preliminary results, but the main 
problem turned out to be the high toxicity profile resulting from the prolonged 
exposure to aminoglycosides, so alternative molecules with less toxicity were 
sought. Ataluren (PTC-124, PTC Therapeutics, South Plainfield, NJ, USA) is one 
of these molecules currently under evaluation with a multicenter phase III study 
(ClinicalTrials.gov Identifier: NCT02139306, started June 2014) PTC-124 uses an 
action mechanism originally described for aminoglycosides allowing the ribosome 
to read premature stop codons without interfering with the true stop signal on the 
mRNA. Studies on CF mice have demonstrated the efficacy of this agent as well 
as the results of some phase II clinical trials (Konstan et al. 2011). PTC-124 not 
only increases the expression and activity of CFTR and improves clinical 
parameters, such as lung function and nasal potential in CF patients, but has also 
been shown to have good tolerability and reduced side effects in prolonged 
treatment of patients (M. Wilschanski et al. 2011). Cystic Fibrosis is not the only 
disease caused by the abnormal presence of PTC induced by the genetic defect. 
Hereditary diseases such as sickle cell anemia and Duchenne muscular dystrophy 
(DMD) share this pathogenetic mechanism. Therefore drugs that are able to 
circumvent the presence of PTC could be useful in the treatment of diseases other 
than CF. So far, clinical tests to assess the effectiveness of Ataluren in DMD 
patients have been rather disappointing (Finkel 2010). However, diseases with 
genetic mutations that induce the presence of PTC could benefit from 
pharmacological research on this class of molecules. 
Correctors. Small molecules are defined CFTR correctors when can increase the 
amount of protein working on the surface of cells with CFTR class II mutations 
such as F508del (Verkman and Galietta 2009; Amaral 2011). To date, hundreds of 
molecular compounds have been identified with corrective characteristics 
(Pedemonte et al. 2005; Van Goor et al. 2006; Carlile et al. 2007; Kalid et al. 
2010; Lin et al. 2010; Van Goor et al. 2011). Based on the mechanism of action, 
these correctors can be distinguished in pharmacological chaperones and in 
protein degradation regulators (proteostasis) (Hanrahan, Sampson, and Thomas 
2013). Until now only a corrector Lumacaftor (VX 809) in association with 
Ivacaftor (VX 770), Orkambi,  has been approved for patients aged 12 years and 
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above who have a the F508del mutation. However Orkambi in more than 1 in 10 
of patient provokes a severe side effect that leads the suspension of administration 
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicine
s/003954/human_med_001935.jsp&mid=WC0b01ac058001d124). As such 
several trials are undergoing with the new corrector VX 661 or other alone or in 
combination with Ivacaftor for patients homozygous for F508del, but seems to be 
necessary the combination of multiple molecules to correct this type of mutations 
and many other compounds are in the pipelines of many biotech companies 
(Mijnders, Kleizen, and Braakman 2017)(Okiyoneda et al. 2013). 
Potentiators. CFTR enhancers increase the likelihood of channel opening and are 
effective in correcting the effects of the presence of Class III (gating) or Class IV 
(conductance) mutations (Van Goor et al. 2009). As the cAMP-PKA signaling 
pathway constitutes the physiologically key step for CFTR activation, the first 
compound tested was IBMX (3-isobutyl-1-methylxan-thine). Drumm (Drumm et 
al. 1991) proposed that IBMX, by inhibiting phosphodiesterase, increases 
intracellular cAMP and consequently PKA activity so that DF508-CFTR can be 
activated to a higher level. Then was demonstrated that genistein, a tyrosine 
kinase inhibitor found in many foods, can activate CFTR in intact cells through a 
mechanism indistinguishable from that of forskolin, an adenylyl cyclase activator 
(B. Illek et al. 1995). Some later studies demonstrated that the CFTR protein itself 
is the target for genistein, establishing for the first time that CFTR itself can serve 
as a target for small-molecule CFTR potentiators (French et al. 1997). Besides 
genistein, other flavonoid molecules have also been shown to enhance CFTR 
function both in vitro and in vivo (Beate Illek and Fischer 1998). 
 
In 2009, by using high throughput drug screening, Vertex Pharmaceuticals 
identified a compound, VX-770, that potently increases the activity of F508del 
CFTR and G551D-CFTR. The VX-770, or Ivacaftor, is a potentiator that 
effectively corrects the defect related to the class III G551D mutation. In vitro 
studies have shown that VX-770 has as its main target CFTR phosphorylated by 
PKA. It also seems to act through a dual mechanism: the first stabilizes the 
 channel in the open form and the second, unconventional, requires neither binding 
of the ATP on NBDs nor its hydrolysis to prolong th
(Figure 4). This would explain why 
defect caused by the G551D mu
binding site. Probably 
inducing a conformational change similar to the dimerization of NDB in the 
presence of ATP. Phosphorylation of CFTR would facili
(Eckford et al. 2012).
VX-770 increases the s
mutation by 10 times, inducing about 50% of the total CFTR activity present in a 
healthy control (Van Goor et al. 2009)
Figure 4. Mechanism of action of 
Based on the results of pre
and Drug Administration (FDA) and the European Medicine Agency (EMA) as an 
orphan drug for all patients with c
G551D. It is marketed under the name Kalydeco (FDA Application No 203188). 
The drug is well tolerated, and at high concentrations (150 mg every 12h, oral 
administration), has proved effec
sweat to a level close to normal (<60 mmol / L). It would also improve lung 
e opening of the canal 
VX-770 is effective in correcting the CFTR 
tation that causes a decreased affinity of the ATP
VX-770 binds to an allosteric site near the two NBDs, 
tate binding access 
 
ecretion of Cl- in bronchial epithelial cells 
. 
 
VX-770(Eckford et al. 2012) 
-clinical studies, in 2012 it was approved by the Food 
ystic fibrosis over 6 years of age with mutation 
tive in decreasing the concentration of Cl
19 
-
with the G551D 
-
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function (mean increase of 9% FEV1) (Verkman and Galietta 2009). Ivacaftor 
restoring the balance of the flow of chloride through the canal would help to 
reduce the excessive activity of amiloride-sensitive channels and the absorption of 
water in epithelial cells with G551D mutation (Verkman and Galietta 2009). 
However, reagents other than VX-770 will be needed to rectify biochemical 
defects that are insensitive to VX-770 (Jih et al. 2017). 
 
Models to study new chemical identity  
Pre-clinical validation of novel compounds correcting CFTR in terms of their 
efficacy is required so that only the best candidates are trialled with patients. 
Unfortunately the impact of a defect in CFTR function differs among tissues and 
cell types, implying that no single CFTR-expressing cell model can accurately 
reproduce all aspects of CF. Moreover, although such tools may serve to facilitate 
personalized approaches to CF intervention, they are unable to report differences 
in corrector and potentiator response among individuals carrying the same CFTR 
mutation, such as caused by polymorphisms in the CFTR gene, CF modifier 
genes, of differences in the CFTR interactome (Ikpa, Bijvelds, and de Jonge 
2014). 
Animal models 
A few years later after the discovery of cftr gene, a first mouse model for CF was 
created (Snouwaert et al. 1992) and start from this, the generation of CF animal 
models has greatly advanced our knowledge of the disease.  
There are many advantages to the use of mice to study the pathology of CF 
disease, including the ease with which they can be genetically manipulated, short 
gestation times, and low cost of animal upkeep (Guilbault et al. 2007). However, 
there are also a number of limitations to their use, for example the mouse models 
fail to initiate spontaneous lung infection without pathogen challenge. Most 
models only display mild complications in the pancreas, liver, and vas deferens, 
which is in contrast to the severe abnormalities in human tissues (Lavelle et al. 
 2016). Although there is a 78% homology between the murine and human CFTR 
protein, a residual function of the 
another channel for 
pathway that may compensate
manipulations (Wilke et al. 2011)
because a lack of CFTR protein and function in CFTR
lungs, liver, pancreas, and GI tract, all organs which are similarly affected in 
humans with CF (Rogers et al. 2008; Ostedgaard et al. 2011)
meconium ileus is present in 100% of 
prevalence of 15% in infants with CF) 
intervention (Rogers et al. 2008)
number of similarities
steps to generate a CFTR
animals to reach adolescence 
pathology mirrors that of humans with CF. Nevertheless, it must be mentioned
that the appearance of lung infections at both the start
ferret life span mirrors human
model. The development
establish the ferret as an exemplary animal model for CF
availability of mouse and other
provides the opportunity to unravel additional pathophysiological details
provides a robust platform to test novel therapeutics for
cystic fibrosis (Rosen et al. 2017)
importance of finding alternative models to the animal model for ethical issues as 
well as to have models that are even closer to the patient's realit
Tab III. Phenotypic manifestations of cystic fibrosis in humans and animal 
models(Lavelle et al. 2016)
channel seems to remain, and 
chloride in epithelial tissue with a alternative signaling 
 the lack of CFTR induced by different gene 
. Pig seems to be a ideal models for study CF, 
−/−piglets impacts on the 
CFTR−/− piglets (in contrast to its 
and it is fatal without early surgical 
. The ferret model does demonstrate a large 
 to CF pathology in humans, particularly neonates.
−/− ferret that overcomes the GI pathology to enable 
are needed to establish whether ferret lung 
 and end of the CFTR
 disease, highlighting the potential benefits of this 
 of F508del and G551D specific mutant is required
 (Lavelle et al. 201
 larger animal models expressing human CFTR 
 many diseases, including 
. However, it is necessary to consider 
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In vitro models 
There are different cell lines used in CF researcher, the most common are 
CFBE41o- and 16HBE14o-, bronchial epithelial cells generated by transformation 
of cystic fibrosis (CF) tracheo-bronchial cells with SV40 (Ehrhardt et al. 2006),  
other are cell lines derived from adenocarcinomas like Calu-3 (submucosal airway 
glands) and T84 (colon) cells are widely used because of their high level of CFTR 
expression, its apical localization when cultured on Transwell® filters, and their 
ability to develop a significant trans-epithelial resistance (Rosen et al. 2017). 
However cell lines are useful during the high throughput screening but they do not 
fully correspond to the reality of the patient. A major step forward was made by 
developing standard protocols for the extraction and maintenance in culture of 
primary Human Airway Epithelial Cells (HAEC)  derived from pulmonary 
biopsies or nasal/bronchi brushes. When HAEC are seeded on Transwell® filters 
and exposed to an air-liquid interface for several weeks, progenitor cells 
differentiate into a pseudostratified epithelium that recapitulates the typical 
mucociliary structure of the airway epithelium (Randell et al. 2011).Among other 
in vitro-based assays to monitor CFTR function organoids have become a model 
of choice for CF research. Organoids are progenitor cells grown in a 3D-
environment in the presence of conditioned medium or supporting cells that 
organize similarly to in vivo organs (with an internal lumen). Organoids 
representative of the intestinal and respiratory systems have been generated and 
these models represent robust systems for screening of drugs that may act alone or 
in combination to correct CFTR channels harboring different mutations (Dekkers 
et al. 2013; Tan et al. 2017). These models unfortunately are not applicable to 
monitoring the patient during a clinical trials or his life, because organoids, as 
HAEC, need several extraction process and some weeks of culture before it is 
possible to assay them. This is one of the reasons why in the last few years the 
interest about leukocytes and monocytes in CF is increased. Already back in 1991, 
(Yoshimura et al. 1991) mRNA encoding for CFTR was demonstrated in human 
leukocytes, but not until recently CFTR protein was detected in neutrophils, 
(Painter et al. 2006), lymphocytes (Shanshiashvili et al. 2012), and monocytes 
(Van de Weert–van Leeuwen et al. 2013; Johansson et al. 2014), in which it was 
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shown to be involved in membrane potential regulation (Sorio et al. 2011). More 
recently the relevance of a mutated CFTR in monocytes has been studied and it 
has been observed that the lack of the channel causes an exaggerated 
inflammatory response at the pulmonary level (Tarique et al. 2017), more in detail 
this phenomenon seems due to a critical regulatory role of CFTR in integrin 
activation by chemo-attractants in monocytes and identify CF as a new, cell type–
selective leukocyte adhesion deficiency disease, providing new insights into CF 
pathogenesis (Sorio et al. 2016). So leukocytes and monocytes seems to be a good 
cellular model to investigate CFTR function in individual patients as these type of 
cells, are easy to collect with a good compliance for the donor. They can be 
readily isolated with minimal handling within a few hours, thus better mirroring 
the original conditions present in vivo. Other researchers start to consider 
leukocytes as a valuable cellular biomarker to be evaluated during the progress of 
a clinical trial (Guerra et al. 2017). 
  
Expression of 
CFTR 
Easy to collect Maintenances 
Cell lines (CFBE41o-
,Clau3,T84) 
Yes 
Yes (possible to 
buy) 
several passages 
HAEC Yes 
Yes (possible to 
buy) 
few passages, 
expensive 
Organoids Yes Long procedure 
several passages, 
expensive 
Leukocytes Yes Yes  max 24h 
 
Tab.IV Summary of the various in vitro models discussed 
 
Methods to measure CFTR activity in different models 
Ussing Chamber.The Ussing chamber provides a physiological system to measure 
the transport of ions, nutrients, and drugs across various epithelial tissues (Clarke 
2009). The method was developed in 1946 by the Danish biologist Hans H. 
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Ussing as a means to understand the phenomenon of active NaCl transport. The 
technique is used to measure the short-circuit current as an indicator of net ion 
transport taking place across an epithelium. Ussing chambers are used to measure 
ion transport in native tissue, such as gut mucosa (rectal biopsy), and in a 
monolayer of airway cells grown on permeable supports (HAEC). When the tissue 
is on the Ussing chamber each side, apical and basal are in contact with the same 
solution, so paracellular ion movements driven by the passive forces of 
transepithelial concentration and osmotic and hydrostatic gradients were 
eliminated. The passive transepithelial driving force created by the spontaneous 
electrical potential across the epithelium is eliminated by clamping the potential to 
zero with an external current passed across the epithelium. This current, known as 
the short-circuit current (Isc), is equivalent to the algebric sum of electrogenic ion 
movement by active transport (i.e., when using conversion with the Faraday 
constant). Thus, by eliminating transepithelial diffusion forces (osmotic and 
electrochemical gradients), the movement of ions as measured by isotopic tracers 
or the short circuit current (Isc) in the Ussing chamber resulted from active 
transport(Clarke 2009). This technique is exploited both to help the diagnosis of 
cystic fibrosis in specialized centers, through rectal biopsies, and for the study of 
new compounds using HAEC.  
Forskolin Induced Swelling (FIS) assay. This recently developed technique is 
used to measure the CFTR activity in organoids derived from CF patients. 
Organoids derived from rectal biopsies after two o more weeks culture, are seeded 
in a proper support, multiwell or chamber slide, the day after are incubated with a 
fluorescent probe, calcein green, for 30 minutes and then analyzed by confocal 
microscopy. After the first acquisition a proper amount of Forskolin is added in all 
well and then a picture is taken after 10 minutes until 60-90 minutes. If the 
treatment is effective, the corrected organoids will show an increase of their 
volume, named swelling. FIS assay was originally developed and proposed by 
Dekkers and colleagues (Dekkers et al. 2013), and is now tested in few 
specialized centers for validation in a clinical context. This technique derives from 
the development of suitable protocols for intestinal stem cell culture and protocols 
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are still being perfected. In addition, qualified personnel and specialized 
infrastructures are required.  
Patch clamp. This is an electrophysiology technique useful to measure ionic 
current in living cells, tissue section or patches of cell membrane. In cystic 
fibrosis it is a validated method to analyze the activity of the CFTR channel in 
different cell types, to deepen its physiological functioning and in the presence of 
different mutations (Linsdell 2016), to verify the response to certain drugs or to 
characterize CFTR in new models (Gonçalves et al. 2017; Salomon et al. 2016; 
Ettorre et al. 2014). It allows obtaining accurate results on the functionality of 
CFTR, however it is low throughput assay, requires high technical skill and 
profound knowledge of electrophysiology as well as a very precise experiment 
setup for each type of cell that is going to be measured. 
Fluorescence probes. Numerous methods have been developed that exploit 
different fluorescent probes to measure the activity of ion channels, often they are 
techniques that require materials and instruments easily available in every 
laboratory and relatively easy to set up and interpret. They are not always able to 
provide with a definitive result, but are useful for the screening of new molecules. 
Among the most used are: MQAE is a 6-methoxyquinolinium derivative and a 
fluorescent indicator for intracellular Cl-, This dye detects the ion via diffusion-
limited collisional quenching (Gonçalves et al. 2017); the potential-sensitive 
probe bis- (1,3-diethylthiobarbituric acid) trimethineoxonol (DiSBAC2(3), 
Invitrogen, USA) can enter in depolarized cells where it binds to intracellular 
proteins or membrane and exhibits enhanced fluorescence and a red spectral shift. 
Increased depolarization results in additional influx of the anionic dye and an 
increase in fluorescence. Conversely, hyperpolarization is indicated by a decrease 
in fluorescence (Renier et al. 1995; Sorio et al. 2011). However, these techniques 
require an incubation time with the probe that goes in direct contact with the cells 
and therefore the interference that the probe with cellular homeostasis must be 
taken into consideration, besides they are methods best suited to be applied on 
adherent cells. 
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Aim of the thesis 
A major challenge for rare diseases such as cystic fibrosis is finding a strategy to 
correct the basic defect and be able to personalize the treatment for each patient. 
Promising drugs able to rescue the expression and function of CFTR are now 
available and many are under advance state of development. These treatments are 
costly and sometimes give rise to serious side effects, setting the need for easy 
and fast methods to be used in primary cells from the individual patients that are 
suitable to predict and monitor their effectiveness as CFTR potentiator/correctors 
in a timely manner. Based on previous work I was involved in the development of 
a new assay to measure CFTR activity. The readout of this method is based on 
residue quantity of iodide present in the supernatant, after proper stimulation, 
quantified by the quenching of the fluorescence of Halide Sensitivity Yellow 
Fluorescence Protein (GST-HS-YFP). The specificity of the assay for CFTR 
activity was tested in CFTR expressing MM6, an acute human monocytic 
leukemia derived cell line, using two selective CFTR inhibitor,CFTR-172 and 
PPQ-102, cells and after silencing of MM6 with CFTR siRNA. I also tested 
primary leukocytes, where we recorded a significant difference between WT and 
CF PBMCs and Monocytes (p<0,005).  
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Materials and Methods 
Reagents  
CFTR activators : 
Forskolin, a cell-permeable diterpenoid that possesses anti-hypertensive, positive 
ionotropic, and adenylyl cyclase activating properties. Many of its biological 
effects are due to its activation of adenylyl cyclase and the resulting increase in 
intracellular cAMP concentration 
Genistein,  inhibitor of tyrosine protein kinase; competitive inhibitor of ATP in 
other protein kinase reactions and a CFTR potentiator (French et al. 1997) and 
N6,2′-O-Dibutyryladenosine 3′,5′-cyclic monophosphate sodium salt (cAMP). To 
verify the accuracy of the assay we treated the cells also whit two different CFTR 
inhibitors: 5-[(4-Carboxyphenyl)methylene]-2-thioxo-3-[(3-
trifluoromethyl)phenyl-4-thiazolidinone (CFTR-inh 172), Ki = 300 nM, 
IC50=0,38µM. CFTR(inh)-172 leads to rapid, reversible and voltage-independent 
inhibition. The 6,7-Dihydro-7,9-dimethyl-6-(5-methyl-2-furanyl)-11-
phenylpyrimido[4',5':3,4]pyrrolo[1,2-a]quinoxaline-8,10(5H,9)-dione (PPQ-102) 
a cell-permeable pyrimido-pyrrolo-quinoxalinedione (PPQ) compound that targets 
the intracellular nucleotide binding domain(s) of CFTR and inhibits CFTR-
mediated chloride current in a reversible and voltage-independent manner with a 
IC50=90nM. For some experiment the corrector Lumacaftor (VX-809) and the 
potentiator Ivacaftor (VX-770) were used at the final concentration of 5µM. 
 
Preparation of recombinant Glutathione S-transferase-Halides sensitive 
Yellow Fluorescent Protein (GST-HS-YFP) 
The recombinant GST-HS-YFP was gently produced and provided by Dr. Monica 
Averna, Department of Experimental Medicine-Biochemistry Section, University 
of Genoa, Italy. The nucleotide sequence of the YFP was amplified by PCR from 
pEYFP-C1 plasmid (Clontech) with the following primers: Sn YFP-BamHI: 5’ 
AA-GGATCC-ATGGTGAGCAAGGGC and Asn YFP-EcoRI: 5’ A-GAATTC-
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TTACTTGTACAGCTCGTCCATGC. Reaction was cycled at an initial 
denaturation temperature of 94°C for 1 min followed by 35 cycles at 94°C for 30 
s, 58°C annealing temperature for 30 s and 68°C extension time for 1 min. A 5-
min extension period at 68°C was incorporated after the last cycle of PCR. Then 
the amplicon has been ligated into pGex6P1 expression vector that contains GST 
(Glutathione S-transferase) as tag protein. To obtain YFP sensitive to halides both 
the mutation YFP-H148Q (Jayaraman et al. 2000) and I152L (Galietta, Haggie, 
and Verkman 2001) were introduced by mutagenesis. Mutagenesis has been 
performed using the polymerase chain reaction-based QuickChange site-directed 
mutagenesis kit (Stratagene) as indicated by the manufacturer. The identity of the 
mutated YFP has been confirmed by sequencing with CEQ 2000XL DNA 
analysis system. (Beckman Coulter). Mutated YFP has been produced in E. Coli 
DH5α as GST-HS-YFP fusion protein and purified to homogeneity following 
affinity chromatography with GSH-agarose. Briefly, transformed DH5α cells 
were grown in Super Broth medium (3.5% tryptone, 2.0% yeast extract, 0.5% 
NaCl, pH 7.0) containing 100 µg/mL ampicillin at 37 °C for 16 h. Cells were then 
ten-fold diluted and grown at 37 °C until optical density at 600 nm was ≥ 0.6. 
Recombinant protein expression was induced with 1.2 mM IPTG (Sigma-Aldrich) 
for 16 h at 25 °C. Cells were washed once with H2O and lysed in the following 
lysis buffer: 0.1 M Tris/HCl pH 8.3, 0.15 M NaCl, 1% Triton-X100, 10 mM 
EDTA, 2 mg/mL lysozyme, 2 µg/mL aprotinin, 100 µg/mL leupeptin, and 2 mM 
AEBSF (2 mL lysis buffer/g). After 20 min at 0 °C, 10 mM MgCl2 and 10 µg/mL 
DNase were added and the lysate was incubated for additional 20 min at 0 °C. The 
lysate was cleared by centrifugation (100,000 ×g for 20 min at 4 °C) and the 
resulting supernatant was loaded onto 2 mL GSH-agarose (Sigma-Aldrich) 
column, pre-equilibrated with 50 mM sodium borate pH 7.5, containing 0.15 M 
NaCl and 5 mM DTT (buffer A). The resin was washed with 20 column volumes 
of buffer A and recombinant GST-HS-YFP was eluted with 50 mM sodium borate 
pH 9.0, containing 0.15 M NaCl, 5 mM DTT, and 10 mM GSH. The eluate was 
submitted to desalting procedure using a PD10 column (GE Healthcare) pre-
equilibrated with 50 mM sodium borate pH 8.0. Purity of GST-HS-YFP was 
evaluated by SDS-10% PAGE followed by blue Coomassie staining. 
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The fusion protein has a KI-= 3.1±0.6 mM (mean±SD; n=8) and a KCl-= 138±26 
(mean±SD; n=4).  
 
Cell culture 
The MM6 (acute human monocytic leukemia) cell line was cultured at 37 °C (5% 
CO2) with RPMI 1640 (Sigma–Aldrich) growth medium containing 10% fetal 
calf serum, 10 U/ml penicillin (Sigma–Aldrich), 100 μg/ml streptomycin (Sigma–
Aldrich) and 4 mM l-glutamine. The MM6 cell line was provided by Prof. 
Claudia Cantoni, Department of Experimental Medicine, University of Genoa, 
Italy. The FRT (Fisher rat thyroid) cell line over-expressing human CFTR (WT 
FRT cells) was cultured at 37 °C (under a 5% CO2 atmosphere) in Coon's F-12 
growth medium, containing 10% (v/v) FBS, 10 units/ml penicillin, 100 μg/ml 
streptomycin, 4 mM L-glutamine and 0.6 mg/ml zeocin. FRT cells not expressing 
human CFTR (FRT non-transfected cells) were cultured in the same medium in 
the absence of zeocin. FRT cell lines were provided by Dr L.J. Galietta, 
Molecular Genetics Laboratory, Giannina Gaslini Institute Genova, Italy. 
Donor subject and sample collection/preparation 
The blood sample from Healthy volunteer or CF patients was collected after 
informed consent by a specialized nurse. For every subject, CF or Healthy donor, 
a sample of 10 ml of blood was collect in two 5 ml BD Vacutainer® tubes 
contained 5mM EDTA. Then the sample was processed to extraction of PBMCs 
(peripheral blood mononuclear cells) or Monocytes. Briefly the whole blood was 
diluted in ratio 1:1 with this buffer: 0,14 M NaCl, 5mM KCl, 2g/L Glucose, 
10mM HEPES in sterile water pH 7,4 and then loaded in a proper amount of 
FicollPaqueTM and centrifuged. The PBMCs fraction was collected with a plastic 
pipette and washed two times with PBS buffer (Fig. 5). To purify the Monocytes 
we used the Monocytes isolation Kit II(MiltenyiBiotec). The magnetically labeled 
non-monocytes are depleted by retaining them on a MACS® Column in the 
magnetic field of a MACS Separator, while the unlabeled monocytes pass through 
the column. After the purification, monocytes were plated in a 96 multi well plate 
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(costar 3596) without Fetal calf serum for 30 minutes and when the cells are 
adherent on plastic the complete medium was added. The day after Monocytes 
were washed twice with CFTR Buffer (0.25 M sucrose, 0,005 M Glucose, 20 mM 
sodium borate and 0.2 mM CaCl2 in sterile water pH 7,5) and then the assay was 
performed. 
 
Figure 5. Representation of density gradient centrifugation with FicollPaqueTM 
YFP Assay 
The principle of this method to measure the CFTR activity in different cell type is 
based on the ability of GST-HS-YFP to change its fluorescence in relation to the 
concentration of iodide present in the medium. The method was originally 
proposed by (Averna et al. 2013) To perform this assay in non-adherent condition 
a proper amount of cells (tab.1) is resuspended in 200µL of CFTR buffer with or 
without stimulus, maintained at 37°C for 10-20 minutes and then exposed to 5mM 
NaI for 20 seconds. Cells are then removed by rapid centrifugation and the 
supernatant recovered. For adherent cells, seeded in 96 mw plate, the volume is 
75µL. The supernatant is transferred in a black plate where 0,5µg of YFP is 
added. The plate is left for 10 minutes in slow agitation and then fluorescence is 
read at λex = 485±15 nm and λem= 535±10 nm. The fluorescence recovery of 
GST-HS-YFP is directly related to the reduced levels of I- due to channel activity. 
The read out of the assay is the difference of fluorescence between stimulus and 
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basal condition where, if CFTR channel is active, a positive difference (delta) is 
recorded; if CFTR channel is not active, no increase in fluorescence is detected. 
Tab.II 
  n° cell/cond 
PBMC 1,5*106 
MM6 200.000 
Monocytes 200.000 
 
 
Figure 6. Schematic view of GST-HS-YFP assay  
Western Blot 
MM6 were lysed in lysis buffer (50 mmol/L Tris, 150 mmol/L NaCl, 1 mmol/L 
EDTA, 1% Triton X-100 pH 7.4) containing protease inhibitors (Roche,Inc.). 
10μg of total protein were separated using 7,5 %(v/v) SDS-PAGE and transferred 
onto nitrocellulose membranes that were probed with monoclonal anti-CFTR 
antibody (Cell Signaling 2269) at a 1:500 dilution, overnight at 4°C. Membranes 
were re probed with monoclonal anti-actin (Sigma-Aldrich) to normalize for 
protein loading. The relative levels of CFTR were estimated by densitometry 
using the ImageJ program (http://rsb.info.nih.gov/ij/). The amount of band C is 
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calculated as a fraction of actin for the respective lane and reported as a fraction of 
the total (band C/actin). The values reported are expressed as means +/-SD (n=3). 
Data sets were compared by a t-test using GraphPad Prism. 
Silencing 
Gene silencing is mean an interruption or suppression of the expression of a gene 
at transcriptional or translational levels. This method generally is able to reduce 
the expression of a gene by at least 70% but do not completely eliminate it. RNA 
interference (RNAi) is a conserved biological response to double-stranded RNA 
that mediates resistance to both endogenous parasitic and exogenous pathogenic 
nucleic acids, and regulates the expression of protein-coding genes. A simplified 
model for the RNAi pathway is based on two steps, each involving ribonuclease 
enzyme. In the first step, the trigger RNA (either dsRNA or miRNA primary 
transcript) is processed into a short, interfering RNA (siRNA) by the RNase II 
enzymes Dicer and Drosha. In the second step, siRNAs are loaded into the 
effector complex RNA-induced silencing complex (RISC). The siRNA is 
unwound during RISC assembly and the single-stranded RNA hybridizes with 
mRNA target. Gene silencing is a result of nucleolytic degradation of the targeted 
mRNA by the RNase H enzyme Argonaute (Slicer). If the siRNA/mRNA duplex 
contains mismatches the mRNA is not cleaved. Rather, gene silencing is a result 
of translational inhibition. (https://www.ncbi.nlm.nih.gov/probe/docs/techrnai/) 
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Figure 7. The image summarizes the process by which exogenous siRNA leads to 
silencing a desired mRNA.  (https://www.scbt.com/scbt/whats-new/gene-
silencers) 
 
The MM6 cells line were transfected with a specific siRNA for CFTR protein 
(s2945, ThermoFisher scientific), or a Silencer® Negative Control (AM4611, 
ThermoFisher scientific) following manual instruction of siPORT™ NeoFX™ 
Transfection Agent (AM4510, ThermoFisher scientific). Briefly, the cells were 
suspended in a concentration of 90.000 cell/ml in a medium with 0,5 % FCS; the 
siPORT™ NeoFX™ Transfection Agent was diluted in RPMI without serum and 
incubated for 10 minutes at RT; then the RNA was diluted in RPMI serum free, 
the siPORT and RNA were mixed together and incubated for other 10 minutes. 
Finally the RNA/siPORT™ NeoFX™ Transfection Agent transfection complexes 
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were dispensed into 12 multi wells of a clean culture plate and the cells were 
added. After 72 hours the functional test YFP assay and Western blot analysis 
were performed.  
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Results 
Analysis of parameters that might affect the assay 
The concentration of 5mM NaI is chosen based on a variation of GST-HS-YFP 
fluorescence according to Iodide concentration. Figure 8A shows a quenching 
curve and it is of note that from 5mM to 0 of NaI the slope of the curve is 
steepest, meaning that for small change in Iodide it is possible record a large 
variation in HS-YFP fluorescence. Furthermore there is no change in pH during 
the test (8B) and no change in fluorescence value in the presence of the stimuli 
without cells (8C). 
 
Figure 8.Panel A: quenching curve of YFP with different concentrations of NaI. 
Panel B: treatment does not alter pH during the test. Panel C: Additions of stimuli 
do not change the fluorescence value in absence of cells. The stimulus added to 
reproduce the experimental condition is 50µM Genistein and 100µM dibutirril-
cAMP for 30 minutes. 
 
The optimal time point for the iodide exchange was investigated in a time course 
experiment. MM6 cell line (fig 9A), PBMC and monocytes (fig 9B) from WT and 
CF individuals were exposed to stimuli from 5 to 20 minutes. Maximum signal 
was recorded at 10 minutes suggesting that after this time there is the maximum 
activation of the CFTR channel and therefore a greater uptake of iodide into the 
cell. So the 10 minutes time was chosen as duration of the stimulus as it provides 
a higher signal to noise ratio suitable to evaluate the increase of the channel 
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activity following different treatments.
 
Figure 9.Panel A. Time course from 5 to 20 minutes of exposure to 10µM of 
Forskolin and 100µM of cAMP in MM6 cell line. Panel B shows the same 
condition applies of PBMC and Monocytes from healthy and CF donor. 
 
HS-YFP assay is specific for CFTR activity 
In order to test the specificity of the assay for CFTR activity, we tested different 
cell models and treatments: Fisher Rat Thyroid (FRT) cell line transfected with 
WT-CFTR, FRTnull clone and MM6 treated with specific siRNA or two different 
chemical inhibitors of CFTR activity. Figure 10, panel A shows the signals 
recorded in FRT cells, the average of three different experiment in FRT with wt 
CFTR is 500, in FRT null is below100, MM6 show a positive delta, while exhibit 
a negative value after siRNA treatment (n=4).Occurrence of siRNA-mediated 
silencing was confirmed by western blot analysis of whole cell lysate. Treatment 
of MM6 with two different CFTR inhibitors, CFTR-inh 172 or PPQ-102, both at 
10µM, causes a significant decrease of the signal (panel C).Usually the accuracy 
of a test to discriminate diseased cases from normal cases is evaluated using 
Receiver Operating Characteristic (ROC) curve analysis (Zweig and Campbell 
1993), in this case the analysis is applied to verify the robustness of the assay in 
discriminate the MM6 treated with specific inhibitors or vehicle(figure 10C). 
Accordingly, PPQ-102 inhibitor has a lower IC50 than CFTR-inh 172 
(IC50172=0,38µM, IC50PPQ102=0,09µM). 
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Figure 10. Analysis of assay specificity. Panel A: no positive fluorescence signal 
is detectable in  FRT null (CFTR negative) or in MM6 treated with a siRNA for 
CFTR, at variance with  FRT cell transfected with wt-CFTR (WT) or mock 
transfected MM6 (scramble) where a positive fluorescence value is detected. 
Stimulus: Forskolin 10µM +dibutyryl 100µM; time 10 minutes - siRNA s2945, 
final concentration 30nM, transfected with siPORTNeoFX transfection agent.  
Panel B confirms the reduction of CFTR protein in MM6 following silencing with 
siRNA for CFTR (s2945). Control is represented by the same cells treated with a 
scramble sequence. CFTR is detected by the anti-CFTR antibody 2269(from Cell 
Signaling).  
Panel C: Similar results were obtained following inhibition of CFTR function in 
MM6 by the chemical inhibitors CFTR-inh 172 or PPQ-102(10µM). ROC curves 
are reported. 
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From cell lines to patients 
Having shown that the signal measured depends on CFTR expression or function 
we move on to further evaluate primary cells from control (Healthy) and CF 
patients. In two different laboratories, the values recorded for PBMCs from 
healthy donor is around 500 fluorescence unit, while PBMCs from CF patients 
present with null or negative values. The performance of a test is evaluated using 
Receiver Operating Characteristic (ROC) curve analysis (figure 11B). The assay 
displays high sensitivity and specificity being capable to discriminate PBMCs 
from CF and Healthy donors. Similar results are obtained using Monocytes (figure 
11D): in this type of cells the value for Healthy control is around 1500 
fluorescence units. If Monocytes from healthy donor are pre-treated with two 
different CFTR-inhibitors, the value is reduced from 1500 to 100 fluorescence 
units, similarly to MM6 cell lines (11C). 
 
Figure 11.Panel A: Results of YFP assay on PBMCs from healthy and CF 
donors, performed by two independent units (Genova and Verona). P<0,01 
ANOVA, Tukey test. Panel B: all data are been grouped and ROC curve is shown.  
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Panel C: Results obtained in monocytes, treated with two different CFTR 
inhibitors 
Panel D: Fluorescence values recorded from healthy and CF monocytes and the 
corresponding ROC curve. 
We also evaluated the response of obligate heterozygous carrying one healthy and 
one mutated CFTR allele. While the test easily discriminate both healthy and 
obligate heterozygous patients, it is unable to identify a partial reduction of CFTR 
function, a condition typical of parents of affected individuals, healthy carriers of 
a mutation in one CFTR gene allele (Fig 12).  
We are now developing a method of analysis that quantifies the exact amount of 
iodide exchanged through a reference curve that will be useful to normalize data 
among different conditions and operators and to reduce the consequences of 
batch-to batch variations of YFP preparations. 
 
Figure 12. The graphic shows the differential fluorescence values recorded from 
PBMCs of non-CF, obligate heterozygotes (Htz) or CF individuals. 
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In support of the hypothesis that this test could be useful in evaluating the efficacy 
of a therapy, we collected samples of a homozygous F508del CF patient and 
evaluated the activity of the CFTR channel on PBMC before the start of Orkambi 
therapy, during and after the suspension. As shown in Figure 13, at time zero (no 
drugs taken) there was no increase of fluorescence, even if using different stimuli, 
after a week of treatment we recorded a positive delta and after one week from the 
suspension of the therapy the activity almost disappeared. 
 
Figure 13. PBMC from CF patient are collected and YFP assay was performed 
before, during and after treatment in vivo with Orkambi therapy and following 
suspension of the therapy (wash out). Stimuli are dibutyryl 100µM; time 10 
minutes for all the condition in combination with: Fsk: Forskolin10µM; Gen: 
Genistein (50µM), VX770 5µM as indicated. 
  
41 
 
Conclusion 
The measurement of CFTR channel activity using this new assay appears specific 
for CFTR function, as demonstrated with the use of different disease models: FRT 
cells transfected with CFTR cDNA or the corresponding CFTR negative cells, 
MM6 cells whose CFTR gene expression is reduced by silencing technology and 
by the use of specific CFTR inhibitors. Finally the results were validated with the 
use of primary cells derived from controls and CF patients. 
PBMCs represent convenient cells fast and easy to purify, and as such, appear 
suitable for monitoring patients during treatment with drugs acting as CFTR 
correctors or potentiators.  
When purified monocytes are cultured these cells can be exposed to the 
compound of interest for a defined time (24-48 hours) and the evaluation of the 
response to CFTR agonist/s can indicate the potential capability of the treatment 
to correct CFTR function in the cells and, by inference, to the individual. Indeed 
CFTR activity in Monocytes was recently found to increase significantly at 3 and 
6 months after Ivacaftor therapy and correlates with FEV1, FVC, BMI(Guerra et 
al. 2017). This suggests that myeloid cells might represent valuable predictive tool 
in CF patients. 
Compared to other techniques already used to monitor the activity of the channel 
through fluorescent probes, such as DiSBAC2(3) or MQAE, this method does not 
require direct contact between the probe and the cells. This is an advantage as it is 
one less variable that can disrupt the system. In addition, the tools required for the 
analysis are easy to use and require short training, while for other techniques such 
as the patch clamp or Ussing chamber in-depth knowledge of electrophysiology 
and more sophisticated tools and expertise are required. GST-HS-YFP assay is a 
method that can find different applications and can be adapted to different cell 
types based on investigative needs, for example as screening tool performed on 
cell lines. Combined with other diagnostic tests already recognized by the 
scientific community, such as the sweat test or ICM, it could represent a valuable 
aid in the diagnosis of cystic fibrosis, particularly in monitoring the efficacy of 
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CFTR correcting therapies in individual patients. These results are still 
preliminary and precise cut off values need to be established along with reference 
curves and quantitative evaluation of iodide exchange.  
The ultimate goal of this study is to develop a test that can accelerate the path 
toward the definition of targeted therapies for each CF patient in an era that 
witness an unprecedented development of combination treatments for this still 
incurable disease. 
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